bluebird bio, Inc. (BLUE)
After hours:
| Previous close | 4.3500 |
| Open | 4.3400 |
| Bid | 4.3700 x 1300 |
| Ask | 4.5000 x 1800 |
| Day's range | 4.2000 - 4.4550 |
| 52-week range | 2.8700 - 8.5800 |
| Volume | |
| Avg. volume | 3,876,939 |
| Market cap | 455.949M |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
SOMERVILLE, Mass., January 19, 2023--bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share, before deducting underwriting discounts and commissions. bluebird also granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions
- Business Wire
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
SOMERVILLE, Mass., January 18, 2023--bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today announced that it has commenced an underwritten public offering of 20,000,000 shares of its common stock. bluebird also intends to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock to be sold in the offering. The offering, actual size and terms are subject to market conditions, and there can be no assurance as to whether or when the offering may be c
- Business Wire
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
SOMERVILLE, Mass., January 09, 2023--bluebird bio, Inc. (Nasdaq: BLUE) (the Company) today announced updates to be presented at the 41st Annual J.P. Morgan Healthcare conference including commercial launch progress, 2023 program milestones and financial outlook. CEO Andrew Obenshain is scheduled to speak on Thursday, January 12 at 7:30 a.m. PT.
